Rhythm isn’t just in their name, it’s in how Iambic engineers the future of medicine. Not rhythm like a beat drop, but the kind that syncs silicon with cell biology, turning data into medicine faster than most startups can sync their calendars. When Iambic Therapeutics announced an oversubscribed $100M+ financing on Nov 10, the applause wasn’t just for the size of the round, it was for the proof that TechBio finally speaks fluently in the language of results.
Founded by Tom Miller, Ph.D., and Fred Manby, Ph.D., Iambic didn’t crawl out of academia to play small. These theoretical chemists turned founders built a machine that doesn’t just think about molecules, it makes them. From a San Diego HQ on Oberlin Drive, their AI platform blends physics-based modeling with automated experimentation, compressing the 6-year drug discovery slog into about 3. That’s not a miracle. That’s precision engineering meeting pure scientific swagger.
IAM1363, their HER2 inhibitor, sprinted from concept to clinic in under 2 yrs and just showed positive data at ESMO 2025: a 28% response rate in measurable systemic disease and 33% in measurable intracranial tumors at ≥960 mg daily. Translation, patients are seeing real effects across HER2-mutant NSCLC, breast, gastric, and renal cancers. Add KIF18A and CDK2/4 programs queued for clinic, and Iambic’s pipeline is looking more like a discography than a demo.
The investor lineup? Elite. Abingworth, Ascenta, Sequoia Capital, Catalio Capital Mgmt, Mubadala, Illumina Ventures, Tao Capital Partners, QIA, Regeneron Ventures, and more. That’s not spray-and-pray capital, it’s conviction capital. NVIDIA, Jazz Pharma, and Revolution Medicines are already in partnership mode, because performance recognizes performance.
